What's Happening?
African institutions are called upon to play a leading role in antimicrobial resistance (AMR) research, influencing the development and testing of next-generation antibiotics and diagnostics. The World Health Organization's 2025 assessments highlighted
ongoing gaps in antibacterial innovation, pediatric formulations, and oral treatments, as well as limited simple diagnostic tools for primary and secondary care. The article emphasizes that surveillance data, such as that from Kenya and Rwanda's expanded Global Antimicrobial Resistance and Use Surveillance System (GLASS), should inform target product profiles for new medical tools. It advocates for African institutions to help define research questions, select meaningful outcomes, and interpret site-specific differences, ensuring that new products are designed for the conditions in which they will be used.
Why It's Important?
The call for African leadership in AMR research is crucial for the global fight against drug-resistant infections, including for the U.S. The unique epidemiological patterns and healthcare challenges in Africa mean that research conducted there can provide invaluable insights into resistance mechanisms and treatment needs that may not be evident elsewhere. By shaping the development of new antibiotics and diagnostics, African institutions can ensure that these tools are relevant, accessible, and effective for diverse populations, including those in resource-limited settings. This approach is vital for a 'One Health' strategy, recognizing that AMR is a global problem requiring solutions tailored to local contexts, ultimately benefiting global public health by preventing the spread of resistance.
What's Next?
The immediate priority is to connect evidence generation with authority over research and investment decisions. Governments and funders should support clinical and laboratory systems in Africa to identify unanswered treatment and prevention questions. Developers are encouraged to involve African institutions early in product specification and trial design. Research agreements should establish meaningful responsibilities in design, analysis, interpretation, and access planning. The Africa Clinical Research Network (ACRN) is positioned to connect institutions around defined questions and shared quality standards. The goal is for African evidence to change development priorities and improve care, ensuring that new antibiotics and diagnostics are designed with the conditions of their intended use in mind.
Beyond the Headlines
This initiative represents a significant shift in the global health research paradigm, moving away from a top-down approach where solutions are primarily developed in high-income countries and then adapted for lower-income settings. By empowering African institutions to lead AMR research, there's an opportunity to foster local innovation, build scientific capacity, and create more equitable partnerships. This approach acknowledges that effective solutions to global health challenges must be rooted in the contexts where they are most needed. It also highlights the ethical imperative to ensure that the benefits of new medical advancements are shared globally, rather than exacerbating existing health disparities. The success of this model could serve as a blueprint for addressing other global health crises, promoting self-sufficiency and tailored solutions.
